

Anergis Appoints Klaus Schollmeier as New Chairman of the Board of Directors

- Senior Pharma and Biotech Executive joins Anergis' Board of Directors as New Chairman

EPALINGES, Switzerland, January 24, 2017 – Anergis SA, a Swiss clinical-stage biopharmaceutical company developing proprietary products for ultra-fast allergy immunotherapy, today announced the appointment of Dr. Klaus Schollmeier as Chairman of its Board of Directors.

Mr. Schollmeier has been a senior executive and advisor to the pharmaceutical and biotech industries for more than 30 years and has senior leadership experience in R&D, Marketing as well as General Management.

“We are delighted and honored to welcome Klaus Schollmeier to Anergis,” said Vincent Charlon, CEO of Anergis. “We are also very grateful to Jacques-François Martin for his support and key contributions during his tenure as Chairman of our Board of Directors from 2012 to 2016.”

“Anergis has successfully collected promising Phase II clinical data on its lead product candidate and I look very much forward to contributing to the company's lead Phase II program and full product pipeline derived from the long contiguous overlapping peptide technology platform,” said Dr. Klaus Schollmeier, the newly elected Chairman.

“It has been a great pleasure to work closely and efficiently with the board and with Vincent Charlon,” added Jacques-François Martin. “I wish Klaus Schollmeier and the Anergis Team all the best in achieving future milestones for the company.”

From 2013 to 2015 Mr. Schollmeier was the CEO of SuppreMol, Munich, Germany, when the company was sold to Baxalta. From 2004 to 2011 he served as CEO of Santhera, Basel, Switzerland, and as Chairman of the Board of Santhera until 2013. Mr. Schollmeier joined Graffinity Pharmaceuticals AG, Heidelberg, Germany, as CEO in 2003, and in 2004 merged the company with MyoContract AG, Basel, Switzerland, to form Santhera. Prior to joining the biotechnology industry in 2003, he was a managing director with the healthcare/biotechnology group at ING-BHF Bank for ING Group Europe. Before then, he spent 16 years in the pharmaceutical industry at BASF, Knoll and Abbott. His scientific roles included Head of Oncology/Immunology Research at BASF's central laboratories in Ludwigshafen, Germany, and, from 1989 to 1993, Senior Director of Biotechnology at BASF Bioresearch Corporation in Cambridge, Massachusetts, USA. He was also a general manager at BASF Pharma Netherlands from 1996 to 1998, and subsequently Vice President and General Manager for Western Europe. Throughout his career he conceived and executed multiple strategic licensing deals and mergers and acquisitions between pharma companies and pharmaceutical and biotech companies. Mr. Schollmeier has a PhD in Biology from the University of Dusseldorf, Germany. In 1991, he became an adjunct research associate professor at Boston University Medical School, Massachusetts, USA.

###

About Anergis

Anergis SA is a Swiss-based biopharmaceutical company specializing in the discovery and development of novel, ultra-fast, proprietary allergy immunotherapy products for the most prevalent

allergies. Anergis' lead-product against birch pollen allergies, AllerT, is in Phase II clinical development. Two additional product candidates against ragweed pollen (AllerR) and house dust mite allergies (AllerDM) are in preclinical development.

Anergis has raised approximately CHF 52 million from private and institutional investors, including BioMedInvest, Renaissance PME, Sunstone Capital, and WJFS, Inc.

About Allergies

Allergies are the most prevalent and fastest growing chronic conditions in the industrialized world, affecting over 500 million people. The only curative therapy of allergies available today, known as “desensitization”, “allergy shots” or “Conventional Allergy Immunotherapy” (AIT), is the process of inducing tolerance to the allergen. It typically requires 3-5 years of treatment and exposes patients to the risk of serious side effects – in particular immediate (<30 min) anaphylactic reactions – which can be life-threatening. With its technology, Anergis is shaping the future of allergy treatment by developing therapeutic modalities that only require 2 months of treatment - compared to 3 to 5 years with currently marketed products.

About Ultra-fast Allergy Immunotherapy and AllerT

AllerT is Anergis' ultra-fast allergy immunotherapy (AIT) against birch pollen allergy originating from the company's proprietary Contiguous Overlapping Peptide (COP) technology platform. COPs are long synthetic peptides that include the full amino acid sequence of one or more natural allergens, which are devoid of the IgE epitopes responsible for the risk of anaphylaxis during immunotherapy with allergens. COP allergy immunotherapy is “ultra-fast” because it only requires a single, 2-month course of treatment to induce long-lasting allergy symptom relief – without repeated treatment in following years.

Today, AllerT is the only ultra-fast AIT treatment with demonstrated clinical efficacy in real-life field-based trials for two consecutive annual pollen seasons and persistent statistically significant elevation in specific immunoglobulin G4 (IgG4) for four consecutive annual pollen seasons, without any repeat treatment after the initial 2-month course.

Studies of COPs targeting bee venom and birch pollen allergies in both animals and humans have consistently demonstrated excellent safety (i.e. no immediate allergic reaction) and immunogenicity (production of specific antibodies and cytokines against the original allergen and establishment of a long-term immune memory).

Contact:

Anergis SA
CH-1066 Epalinges
Vincent Charlon, CEO
info@anergis.ch

Media Inquiries:

akampion
Dr. Ludger Wess, Ines-Regina Buth
Managing Partners
Tel. +49 40 88165964 or +49 30 2363 2768
info@akampion.com